CD64/CD28/CD3ζ T cells could significantly impact the rational design of personalized studies to treat CRC and SCCHN and the identification of novel FcγR ALs in cancer and healthy cells. The gene discussed is FCGR1A; the disease is head and neck squamous cell carcinoma.